Latest Diagnostics News

Genetic Signatures has completed a major restructure delivering $5 million in annual savings from FY2027 and secured a decade-long supply contract with Denmark’s Hvidovre Hospital, while posting $14.8 million revenue for FY2026 amid market pressures.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

Artrya has launched its AI-powered Salix platform at Northeast Georgia Health System, marking its second U.S. commercial customer with active revenue streams from subscription and fee-per-scan models.

Proteomics International has locked in a three-year exclusive distribution deal with Healius, leveraging its extensive pathology network to roll out its Promarker® diagnostic tests nationally from FY27.

Radiopharm Theranostics reported robust Phase 2b results for RAD101 in brain metastases imaging, hitting 93% concordance with MRI and setting the stage for a U.S. Phase 3 trial. Meanwhile, its Phase 1 trial of RAD204 showed durable partial responses and good tolerability in advanced solid tumors.

Lumos Diagnostics is accelerating the rollout of its rapid FebriDx test in the US, with a top 100 urgent care group deploying across 30+ sites and three tier 1 groups validating the test across 230+ locations.

Optiscan Imaging has fast-tracked Stage 2 of its pioneering head and neck cancer imaging study, moving into live intraoperative imaging ahead of schedule. This advancement supports FDA regulatory efforts and enhances the company’s AI imaging development.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Botala Energy’s Pitse Pilot well 3.5B in Botswana has successfully completed hydraulic stimulation and entered commercial production testing, marking a critical step toward establishing gas flow rates above 70 GJ/day.

Imricor Medical Systems has submitted its final 510(k) devices to the FDA, marking a major step towards commercialising its MRI-guided cardiac catheterisation platform in the US.

AnteoTech has secured independent validation for its Ultranode™ 95 silicon anode in commercial drone battery cells, launched a new battery additive, and strengthened its cash position with a A$10 million capital raise.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.